Clinical Trial Update: Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies [EARLY_Phase 1]

View source ↗

Summary

Exploratory in vivo CAR-T therapy targeting CD20 is being studied in hematologic malignancies in a Phase 1 trial that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CD20-targeted CAR-T therapy

Snippet

Sponsor: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | Conditions: Hematological Malignancies | EARLY_Phase 1 | Status: NOT_YET_RECRUITING